Morphotek, Inc. is a biopharmaceutical company focused on the discovery and development of therapeutic monoclonal antibodies (mAbs) for the treatment of cancer, inflammatory and infectious diseases. Morphotek develops these antibodies through the use of its proprietary human antibody technologies, Human MORPHODOMA^® and Libradoma™. Two of the company’s mAb programs are currently in clinical trials for the treatment of ovarian cancer and pancreatic cancer with several others in preclinical development.

Headquartered in Exton, PA, Morphotek is a U.S. subsidiary of Eisai Co., a research-based human health care (hhc) company seeking innovative solutions in disease prevention, cure and care for the health and well-being of people worldwide.

Read more about Morphotek...